These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 33333800)

  • 1. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy.
    Shaik F; Cuthbert GA; Homer-Vanniasinkam S; Muench SP; Ponnambalam S; Harrison MA
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33333800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF-A121a binding to Neuropilins - A concept revisited.
    Sarabipour S; Mac Gabhann F
    Cell Adh Migr; 2018 May; 12(3):204-214. PubMed ID: 29095088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells.
    Sarabipour S; Kinghorn K; Quigley KM; Kovacs-Kasa A; Annex BH; Bautch VL; Mac Gabhann F
    PLoS Comput Biol; 2024 Feb; 20(2):e1011798. PubMed ID: 38324585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases.
    Shibuya M
    Endocr Metab Immune Disord Drug Targets; 2015; 15(2):135-44. PubMed ID: 25772179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.
    Smith GA; Fearnley GW; Tomlinson DC; Harrison MA; Ponnambalam S
    Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26285805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches.
    Mac Gabhann F; Popel AS
    PLoS Comput Biol; 2006 Dec; 2(12):e180. PubMed ID: 17196035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF.
    Neufeld G; Kessler O; Herzog Y
    Adv Exp Med Biol; 2002; 515():81-90. PubMed ID: 12613545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF Receptor Tyrosine Kinases: Key Regulators of Vascular Function.
    Álvarez-Aznar A; Muhl L; Gaengel K
    Curr Top Dev Biol; 2017; 123():433-482. PubMed ID: 28236974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF receptor protein-tyrosine kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2008 Oct; 375(3):287-91. PubMed ID: 18680722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGFR endocytosis: Implications for angiogenesis.
    Saikia Q; Reeve H; Alzahrani A; Critchley WR; Zeqiraj E; Divan A; Harrison MA; Ponnambalam S
    Prog Mol Biol Transl Sci; 2023; 194():109-139. PubMed ID: 36631189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.
    Zachary I; Gliki G
    Cardiovasc Res; 2001 Feb; 49(3):568-81. PubMed ID: 11166270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
    Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
    J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
    Lohela M; Bry M; Tammela T; Alitalo K
    Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and function of vascular endothelial growth factor and its receptor system.
    Park SA; Jeong MS; Ha KT; Jang SB
    BMB Rep; 2018 Feb; 51(2):73-78. PubMed ID: 29397867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features.
    Nieminen T; Toivanen PI; Rintanen N; Heikura T; Jauhiainen S; Airenne KJ; Alitalo K; Marjomäki V; Ylä-Herttuala S
    Biochim Biophys Acta; 2014 Jan; 1840(1):454-63. PubMed ID: 24112971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.
    Geretti E; van Meeteren LA; Shimizu A; Dudley AC; Claesson-Welsh L; Klagsbrun M
    Mol Cancer Res; 2010 Aug; 8(8):1063-73. PubMed ID: 20651020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.